Contact Us

Strattera
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Eli Lilly Off on Drug Label Warning

Dec 17, 2004 | www.thestreet.com

Eli Lilly shares fell Friday after the company said it has added a bolded warning to the product label for Strattera, its treatment for attention deficit/hyperactivity disorder, or ADHD.

The company said the warning states the medication should be discontinued in patients with jaundice or laboratory evidence of liver injury. Lilly said the label change is the result of two reported cases of severe liver injury out of the more than 2 million patients who have taken the medication since approval. Both patients have recovered with normal liver function after discontinuing the medication.

Lilly said it had "worked closely" with the Food and Drug Administration "to determine the best course of action, and as a result, are taking a number of measures to notify health care professionals and ultimately patients."

The drugmaker stressed that the 6,000 patients taking Strattera in clinical trials did not show liver injury. "Real-world reports indicate that Strattera can cause severe liver injury in rare cases," the company said.

ADHD affects 3% to 7% of school-age children and manifests itself in levels of attention, concentration, activity, distractibility and impulsivity that are inappropriate for the age group, according to the company's news release.

Shares fell $2.04, or 3.5%, to $55.36.


Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo